Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis

Barchiesi, Francesco; Spreghini, Elisabetta; Tomassetti, Serena; Della Vittoria, Agnese; Arzeni, Daniela; Manso, Esther; Scalise, Giorgio

doi:10.1128/aac.00111-06

Cited by 98Antifungal resistance and susceptibilityFungal Infections and StudiesYeasts and Rust Fungi Studies

Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis

Open access

Barchiesi, Francesco, Spreghini, Elisabetta, Tomassetti, Serena, Della Vittoria, Agnese, Arzeni, Daniela, Manso, Esther, Scalise, Giorgio·2006·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.00111-06

Open this paper in CoChat — free account

Abstract

The in vitro activity of caspofungin (CAS) was investigated against 28 yeast isolates belonging to Candida albicans ( n = 5), Candida guilliermondii ( n = 10), and Candida parapsilosis ( n = 13). CAS MICs obtained by broth dilution and Etest methods clearly showed a rank order of susceptibility to the echinocandin compound with C. albicans > C. parapsilosis > C. guilliermondii . Similarly, time-kill assays performed on selected isolates showed that CAS was fungistatic against C. albicans and C. parapsilosis , while it did not exert any activity against C. guilliermondii . In a murine model of systemic candidiasis, CAS given at doses as low as 1 mg/kg of body weight/day was effective at reducing the kidney burden of mice infected with either C. albicans or C. guilliermondii isolates. Depending on the isolate tested, mice infected with C. parapsilosis responded to CAS given at 1 and/or 5 mg/kg/day. However, the overall CFU reduction for C. guilliermondii and C. parapsilosis was approximately 100-fold less than that for C. albicans . Our study shows that CAS was active in experimental systemic candidiasis due to C. guilliermondii and C. parapsilosis , but this activity required relatively high drug dosages.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.00111-06

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Intrinsic FKS mutations result in elevated MIC levels but lower level of reduced β-1,3-d-glucan synthase sensitivity compared with acquired FKS mutations.
“intrinsic FKS mutations, also resulting in elevated MIC levels (but in a lower level of reduced β-1,3-d-glucan synthase sensitivity when compared with the acquired FKS mutations) [118,120,121].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [120]
Application of Etest agar-based technology to determine amphotericin B MICs in a broad antifungal surveillance program has identified specific differences in the susceptibilities of the various species of Candida to amphotericin B.
“Application of the Etest agar-based technology to determine amphotericin B MICs in the context of a broad antifungal surveillance program has identified specific differences in the susceptibilities of the various species of Candida to this former 'gold standard' antifungal agent (Table 10) (20, 92, 113, 136, 202, 207, 212, 215, 323).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [20]
Blignaut and colleagues reported that among the five distinct DNA clades of C. albicans, the South African clade contained a significantly higher proportion of amphotericin B-resistant (MIC ≥2 μg/ml) isolates (16% of 179 isolates) than did the other four clades (5.4% of 167 isolates).
“Recently, Blignaut and colleagues (20) reported that among the five distinct DNA clades of C. albicans , the South African clade (clade SA) contained a significantly higher proportion of amphotericin B-resistant (MIC ≥ 2 𝛍 g/ ml) isolates (16% of 179 isolates) than did the other four clades (5.4% of 167 isolates).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [20]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736 · see citing works
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · see citing works
Echinocandin antifungal drugs
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · see citing works
Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszyńska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 905 · see citing works
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyondCandida albicansandAspergillus fumigatus
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 695 · see citing works
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky‐Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N. E., Kauffman, C. A., Cleary, J. D., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 494 · see citing works
Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization
Pfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352 · see citing works
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors
Douglas, C. M., D'Ippolito, J. A., Shei, G.-J., Meinz, M., Onishi, J. C., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A. M., Bartizal, K. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344 · see citing works
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K. F., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311 · see citing works
A Randomized Double‐Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308 · see citing works
Current Treatment Strategies for Disseminated Candidiasis
Spellberg, B. J., Filler, S. G., & Edwards, J. E. (2005) · Clinical Infectious Diseases · doi:10.1086/499057 · Cited by 253 · see citing works
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
Abruzzo, G. K., Flattery, A. M., Gill, C. J., Kong, L., Smith, J. G., Pikounis, V. B., Balkovec, J. M., Bouffard, A., Dropinski, J. F., Rosen, H., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2333 · Cited by 241 · see citing works
Untitled work
(2003) · PubMed · Cited by 240 · see citing works
Emergence of Fluconazole Resistance in a Candida parapsilosis Strain That Caused Infections in a Neonatal Intensive Care Unit
Sarvikivi, E., Lyytikäinen, O., Soll, D. R., Pujol, C., Pfaller, M. A., Richardson, M. D., Koukila-Kähkölä, P., Luukkainen, P., & Saxén, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.6.2729-2735.2005 · Cited by 177 · see citing works
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species
Odds, F. C., Motyl, M. R., Andrade, R. A., Billé, J., Cantón, E., Cuenca‐Estrella, M., Davidson, A. D., Durussel, C., Ellis, D., Foraker, E., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3475-3482.2004 · Cited by 173 · see citing works
Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity
Louie, A., Deziel, M. R., Liu, W., Drusano, M. F., Gumbo, T., & Drusano, G. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5058-5068.2005 · Cited by 163 · see citing works
Caspofungin Resistance in<i>Candida albicans</i>: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis
Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162 · see citing works
In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of <i>Candida</i> spp., Including 315 Isolates Resistant to Fluconazole
Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.11.5425-5427.2005 · Cited by 161 · see citing works
In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates
Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1068-1071.2003 · Cited by 152 · see citing works
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome
Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 137 · see citing works
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of Candida Species
Barchiesi, F., Schimizzi, A. M., Fothergill, A. W., Scalise, G., & Rinaldi, M. G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/pl00015011 · Cited by 74 · see citing works
Self-citation
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
Graybill, J. R., Bocanegra, R. A., Luther, M., Fothergill, A. W., & Rinaldi, M. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.1937 · Cited by 68 · see citing works
In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies
Bonaventura, G. D., Spedicato, I., Picciani, C., D’Antonio, D., & Piccolomini, R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4453-4456.2004 · Cited by 51 · see citing works
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of
Barchiesi, F., Schimizzi, A. M., Fothergill, A. W., Scalise, G., & Rinaldi, M. G. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050283 · Cited by 43 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · see citing works
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901 · see citing works
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351 · see citing works
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327 · see citing works
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267 · see citing works
Elevated Chitin Content Reduces the Susceptibility of Candida Species to Caspofungin
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01486-12 · Cited by 214 · see citing works
Increasing incidence of Candida parapsilosis candidemia with caspofungin usage.
Forrest, G. N., Weekes, E., & Johnson, J. K. (2008) · Journal of Infection · doi:10.1016/j.jinf.2007.10.014 · Cited by 144 · see citing works
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129 · see citing works
Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy
Kabbara, N., Lacroix, C., Peffault de Latour, R., Socie, G., Ghannoum, M., & Ribaud, P. (2008) · Haematologica · doi:10.3324/haematol.11149 · Cited by 61 · see citing works
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26 · see citing works

Caspofungin: the first licensed antifungal drug of the novel echinocandin class
DiNubile, M. J., Motyl, M. R., & Sable, C. A. (2004) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2004.05.001 · Cited by 3 · see citing works
The pharmacology and clinical use of caspofungin
Hope, W. W., Shoham, S., & Walsh, T. J. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.263 · Cited by 28 · see citing works
Faculty Opinions recommendation of Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Timsit, J. (2015) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718009732.793502935
Caspofungin therapy in immunocompromised children and neonates
Somer, A., Törün, S. H., & Salman, N. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.4 · Cited by 9 · see citing works
The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Murine Model of Candida glabrata Colonization and Systemic Dissemination
Healey, K. R., Nagasaki, Y., Zimmerman, M. D., Kordalewska, M., Park, S., Zhao, Y., & Perlin, D. S. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01412-17 · Cited by 56 · see citing works

Authors: Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G.
Affiliations: Marche Polytechnic University (IT)
Istituto di Malattie Infettive e Medicina Pubblica, Università Politecnica delle Marche
Azienda Ospedaliero-Universitaria delle Marche (IT)
Corresponding author: Barchiesi, Francesco
ORCID: Barchiesi, Francesco
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2006-08
Volume: 50
Issue: 8
Pages: 2719-2727
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.00111-06
OpenAlex: W2136899085
Cited by: 98
References: 24
Citations by year: 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 4 · 2014: 10 · 2013: 4 · 2012: 7
FWCI: 5.58
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
Keywords: caspofungin, echinocandins, Candida guilliermondii, Candida parapsilosis, Candida albicans, systemic candidiasis, antifungal susceptibility, fungistatic activity, time-kill kinetics, mouse model, kidney fungal burden, minimum inhibitory concentration
MeSH terms: Caspofungin, Animals, Antifungal Agents, Candida, Candida albicans, Candidiasis, Dose-Response Relationship, Drug, Humans, Injections, Intravenous, Male, Mice, Inbred Strains, Microbial Sensitivity Tests, Peptides, Cyclic, Species Specificity, Time Factors, Colony Count, Microbial, Mice, Echinocandins, Lipopeptides, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks